http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-030244-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c902faf6ae746c51fc8010672fc22894 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D217-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D217-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-472 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2001-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2003-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-030244-A1 |
| titleOfInvention | HETEROCICLIC CARBOXAMIDS, PHARMACEUTICAL COMPOSITIONS, THE USE OF THE SAME FOR THE MANUFACTURE OF ANTIVIRAL MEDICINES AND AN IN VITRO METHOD TO INHIBIT THE VIRAL DNA POLYMERASE |
| abstract | Heterocyclic carboxamides, comprising a compound of formula (1) where: X is Cl, Br, F, CN or NO2; G is C3-7 alkyl, partially unsaturated and substituted by hydroxy, or C1-7 alkyl substituted by NR1R2 or 4-tetrahydropyran; R1 is C2-7 alkyl substituted by hydroxy; C1-4 alkoxy, aryl, or heteroaryl; R2 is hydrogen or C1-7 alkyl; or R1 and R2, together with the nitrogen to which they are attached, form morpholine, which may be optionally substituted by aryl or C1-7 alkyl; W is a compound of formula (2); B is CR5 or nitrogen; C is CR6 or nitrogen; with the proviso that B and C cannot be both nitrogen; R4 is H, halogen, or C1-4 alkyl, optionally substituted by one to three halogens; R5 is H, halo, OR12, SR12, C1-7 alkyl, which may be partially unsaturated and may be optionally substituted by one or more substituents selected from the group consisting of OR12, SR12, NR10R11, or halo; C3-8 cycloalkyl, which may be partially unsaturated and may be optionally substituted by one or more substituents selected from the group consisting of halogen, OR12, SR12, or NR10R11; (C = O) R9, S (O) mR9, (C = O) OR2, NHSO2R9, nitro, or cyano; R6 is H, halo, aryl, het, or R7; R7 is OR12, SR12, C1-7 alkyl, which may be partially unsaturated and may be optionally substituted by one or more substituents selected from the group consisting of OR12, SR12, NR10R11, aryl, halo, C3-8 cycloalkyl, substituted optionally by OR12, or het bound by means of a C atom; NR10R11, C3-8 cycloalkyl, which may be partially unsaturated and may be optionally substituted by one or more substituents selected from the group consisting of halogen, OR12, SR12 or NR10R11; (C = O) R9, S (O) mR9, (C = O) OR2, NHSO2R9, nitro, or cyano; R8 is H, C1-7 alkyl, which may be partially unsaturated and may be optionally substituted by one or more substituents selected from the group consisting of OR12, SR12, NR10R11, or halo; OR12, or SR12; R9 is C1-7 alkyl, NR10R11, aryl, or het, wherein said het is linked by means of a C atom; R10 and R11 are, independently, H, aryl, C1-7 alkyl, which may be partially unsaturated and may be optionally substituted by one or more substituents selected from the group consisting of CONR2R2, CO2R2, het, aryl, cyano, or halo; C2-7 alkyl, which may be partially unsaturated and is replaced by one or more substituents selected from the group consisting of NR2R2, OR2, or SR2; C3-8 cycloalkyl, which may be partially unsaturated and may be optionally substituted by one or more substituents selected from the group consisting of halogen, OR2, SR2, or NR2R2; or R10 and R11, together with the nitrogen to which they are attached, form a het; R12 is H, aryl, het, C1-7 alkyl, optionally substituted by aryl, het, or halogen; C2-7 alkyl substituted by OR2, SR2, or NR2R2; or C3-8 cycloalkyl, which may be partially unsaturated and may be optionally substituted by one or more substituents selected from the group consisting of halogen, OR2, SR2, or NR2R2; each m is independently 1 or 2; aryl is a phenyl radical or an oxyfused bicyclic carbocyclic radical in which at least one ring is aromatic, and the aryl can be optionally substituted by one or more substituents selected from the group consisting of halo, OH, cyano, NR2R2, CO2R2, CF3, C1-6 alkoxy, and C1-6 alkyl which can be additionally substituted by one to three groups SR2, NR2R2, OR2, or CO2R2; het is a 4, 5, 6 or 7 membered heterocyclic ring, saturated or unsaturated, having 1, 2 or 3 heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, which optionally fuses to a ring of benzene, or any bicyclic heterocyclic group, and het may be optionally substituted by one or more substituents selected from the group consisting of halo, OH, cyano, phenyl, CO2R2, CF3, C1-6 alkoxy, oxo, oxime and C1 alkyl -6 which may be additionally substituted by one to three groups SR2, NR2R2, OR2, or CO2R2; halo or halogen is F, Cl, Br or I; 1 represents the point of union between W and G; 2 represents the point of union between W and the carbonyl group of formula (1); and a pharmaceutically acceptable salt thereof; pharmaceutical compositions that comprise them and the use thereof for the manufacture of medicaments that are useful as antiviral agents, in particular as agents against herpes family viruses and in vitro method to inhibit viral DNA polymerase. |
| priorityDate | 2000-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 56.